THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS

In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment until disorder progression or perhaps the contributors are not able to tolerate the study drugs.88 These preclinical studies provide paradigms for potential clinical trials in AML, and the